These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 1087288)
1. A comparison of physical and cytogenetic estimates of radiation dose in patients treated with iodine-131 for thyroid carcinoma. Llloyd DC; Purrott RJ; Dolphin GW; Horton PW; Halnan KE; Scott JS; Mair G Int J Radiat Biol Relat Stud Phys Chem Med; 1976 Nov; 30(5):473-85. PubMed ID: 1087288 [TBL] [Abstract][Full Text] [Related]
2. Cytogenetic study of radiation burden in thyroid disease patients treated with external irradiation or radioiodine. Gundy S; Katz N; Füzy M; Esik O Mutat Res; 1996 Jun; 360(2):107-13. PubMed ID: 8649463 [TBL] [Abstract][Full Text] [Related]
3. [Cytogenetic study of thyroid patients treated with external irradiation or radioiodine]. Katz N; Esik O; Füzy M; Gundy S Orv Hetil; 1998 Jun; 139(25):1521-6. PubMed ID: 9676113 [TBL] [Abstract][Full Text] [Related]
4. Cytogenetic biodosimetry and dose-rate effect after radioiodine therapy for thyroid cancer. Khvostunov IK; Saenko VA; Krylov V; Rodichev A; Yamashita S Radiat Environ Biophys; 2017 Aug; 56(3):213-226. PubMed ID: 28526978 [TBL] [Abstract][Full Text] [Related]
5. Biological dosimetry in patients treated with iodine-131 for differentiated thyroid carcinoma. M'Kacher R; Legal JD; Schlumberger M; Voisin P; Aubert B; Gaillard N; Parmentier C J Nucl Med; 1996 Nov; 37(11):1860-4. PubMed ID: 8917193 [TBL] [Abstract][Full Text] [Related]
6. Chromosome aberrations after treatment with radioactive iodine for thyroid cancer. Baugnet-Mahieu L; Lemaire M; Léonard ED; Léonard A; Gerber GB Radiat Res; 1994 Dec; 140(3):429-31. PubMed ID: 7972697 [TBL] [Abstract][Full Text] [Related]
7. Measurement of the radioactive body burden in patients receiving iodine-131 treatment for carcinoma of the thyroid. Ravichandran R; Supe SS; Jayasree U; Devaru S Eur J Nucl Med; 1997 Apr; 24(4):464. PubMed ID: 9198581 [No Abstract] [Full Text] [Related]
8. Cytogenetic and dosimetric effects of (131)I in patients with differentiated thyroid carcinoma: comparison between stimulation with rhTSH and thyroid hormone withdrawal treatments. da Silva MA; Valgôde FG; Gonzalez JA; Yoriyaz H; Guimarães MI; Ribela MT; Buchpiguel CA; Bartolini P; Okazaki K Radiat Environ Biophys; 2016 Aug; 55(3):317-28. PubMed ID: 27013085 [TBL] [Abstract][Full Text] [Related]
9. Equal induction and persistence of chromosome aberrations involving chromosomes 1, 4 and 10 in thyroid cancer patients treated with radioactive iodine. Puerto S; Marcos R; Ramírez MJ; Galofré P; Creus A; Surrallés J Mutat Res; 2000 Aug; 469(1):147-58. PubMed ID: 10946251 [TBL] [Abstract][Full Text] [Related]
10. DNA Damage in Peripheral Blood Lymphocytes of Thyroid Cancer Patients After Radioiodine Therapy. Eberlein U; Scherthan H; Bluemel C; Peper M; Lapa C; Buck AK; Port M; Lassmann M J Nucl Med; 2016 Feb; 57(2):173-9. PubMed ID: 26564321 [TBL] [Abstract][Full Text] [Related]
11. Cytokinesis-block micronucleus test in patients undergoing radioiodine therapy for differentiated thyroid carcinoma. Popova L; Hadjidekova V; Hadjieva T; Agova S; Vasilev I Hell J Nucl Med; 2005; 8(1):54-7. PubMed ID: 15886755 [TBL] [Abstract][Full Text] [Related]
12. Blood dosimetry and dose-rate effects after radioiodine therapy of differentiated thyroid cancer. Lassmann M; Luster M; Hänscheid H; Reiners C J Nucl Med; 2005 May; 46(5):899. PubMed ID: 15872368 [No Abstract] [Full Text] [Related]
13. Biologic dosimetry in thyroid cancer patients after repeated treatments with iodine-131. M'Kacher R; Schlumberger M; Légal JD; Violot D; Béron-Gaillard N; Gaussen A; Parmentier C J Nucl Med; 1998 May; 39(5):825-9. PubMed ID: 9591584 [TBL] [Abstract][Full Text] [Related]
14. Evidence of increased chromosomal abnormalities in French Polynesian thyroid cancer patients. Violot D; M'Kacher R; Adjadj E; Dossou J; de Vathaire F; Parmentier C Eur J Nucl Med Mol Imaging; 2005 Feb; 32(2):174-9. PubMed ID: 15449047 [TBL] [Abstract][Full Text] [Related]
15. 131I Biokinetics and cytogenetic dose estimates in ablation treatment of thyroid carcinoma. Nascimento AC; Lipsztein JL; Corbo R; Rebelo AM Health Phys; 2010 Oct; 99(4):457-63. PubMed ID: 20838086 [TBL] [Abstract][Full Text] [Related]
16. Cytogenetic effects of radioiodine therapy: a 20-year follow-up study. Livingston GK; Khvostunov IK; Gregoire E; Barquinero JF; Shi L; Tashiro S Radiat Environ Biophys; 2016 May; 55(2):203-13. PubMed ID: 27015828 [TBL] [Abstract][Full Text] [Related]
17. Correlation between external exposure and activity in patients undergoing 131I thyroid cancer therapy. Barquero R; Basurto F; Vega-Carrillo HR; Iñiguez MP; Ferrer N; Esteban R Health Phys; 2008 Aug; 95(2):227-33. PubMed ID: 18617804 [TBL] [Abstract][Full Text] [Related]
18. Calculation of Blood Dose in Patients Treated With 131I Using MIRD, Imaging, and Blood Sampling Methods. Piruzan E; Haghighatafshar M; Faghihi R; Entezarmahdi SM Medicine (Baltimore); 2016 Mar; 95(11):e3154. PubMed ID: 26986171 [TBL] [Abstract][Full Text] [Related]
19. Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma. Hänscheid H; Lassmann M; Luster M; Kloos RT; Reiners C Endocr Relat Cancer; 2009 Dec; 16(4):1283-9. PubMed ID: 19628649 [TBL] [Abstract][Full Text] [Related]
20. Treatment of medullary carcinoma of the thyroid with I-131. Nusynowitz ML; Pollard E; Benedetto AR; Lecklitner ML; Ware RW J Nucl Med; 1982 Feb; 23(2):143-6. PubMed ID: 7057256 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]